Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Gieseler, Robert K
MetadataShow full item record
AbstractTargeted drug delivery systems hold promise for selective provision of active compounds to distinct tissues or cell subsets. Thus, locally enhanced drug concentrations are obtained that would confer improved efficacy. As a consequence adverse effects should be diminished, as innocent bystander cells are less affected. Currently, several controlled drug delivery systems based on diverse materials are being developed. Some systems exhibit material-associated toxic effects and/or show low drug loading capacity. In contrast, liposomal nanocarriers are particularly favorable because they are well tolerated, poorly immunogenic, can be produced in defined sizes, and offer a reasonable payload capacity. Compared with other immune cells, professional antigen-presenting cells (APCs) demonstrate enhanced liposome uptake mediated by macropinocytosis, phagocytosis and presumably also by clathrin- and caveolae-mediated endocytosis. In order to further enhance the targeting efficacy toward APCs, receptor-mediated uptake appears advisable. Since APC subsets generally do not express single linage-specific receptors, members of the C-type lectin receptor (CLR) family are compelling targets. Examples of CLR expressed by APCs include DEC-205 (CD205) expressed by myeloid dendritic cells (DC) and monocytes, the mannose receptor C type 1 (MR, CD206) expressed by DC, monocytes and macrophages, DC-SIGN (CD209) expressed by DC, and several others. These receptors bind glycans, which are typically displayed by pathogens and thus support pathogen uptake and endocytosis. Further research will elucidate whether glycan-decorated liposomes will not only enhance APCs targeting but also enable preferential delivery of their payload to discrete subcellular compartments.
CitationAntigen presenting cell-selective drug delivery by glycan-decorated nanocarriers. 2015, 95 (Pt A):13-7 Eur J Pharm Biopharm
AffiliationTWINCORE, Centre for Experimental and Clinical Infection Research GmbH, Feodor-Lynen-Str. 3-7, 30625 Hannover, Germany.
JournalEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V
The following license files are associated with this item:
- Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
- Authors: Fehres CM, Kalay H, Bruijns SC, Musaafir SA, Ambrosini M, van Bloois L, van Vliet SJ, Storm G, Garcia-Vallejo JJ, van Kooyk Y
- Issue date: 2015 Apr 10
- Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
- Authors: Unger WW, van Beelen AJ, Bruijns SC, Joshi M, Fehres CM, van Bloois L, Verstege MI, Ambrosini M, Kalay H, Nazmi K, Bolscher JG, Hooijberg E, de Gruijl TD, Storm G, van Kooyk Y
- Issue date: 2012 May 30
- DC-SIGN mediated antigen-targeting using glycan-modified liposomes: formulation considerations.
- Authors: Joshi MD, Unger WW, van Beelen AJ, Bruijns SC, Litjens M, van Bloois L, Kalay H, van Kooyk Y, Storm G
- Issue date: 2011 Sep 20
- C-type lectin receptor SIGNR1 expressed on peritoneal phagocytic cells with an immature dendritic cell-like phenotype is involved in uptake of oligomannose-coated liposomes and subsequent cell maturation.
- Authors: Kawauchi Y, Igarashi M, Kojima N
- Issue date: 2014 Feb
- MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses.
- Authors: Boks MA, Ambrosini M, Bruijns SC, Kalay H, van Bloois L, Storm G, Garcia-Vallejo JJ, van Kooyk Y
- Issue date: 2015 Oct 28